What this page is
Two paths people describe
Reading through public self-reports on r/Opioid_RCs and r/researchchemicals[1], two broad approaches emerge for people trying to stop using their primary opioid (kratom, fentanyl, nitazenes, prescription opioids, methadone, buprenorphine, ODSMT):
Cold turkey
Stop the original opioid, take nothing in its place, ride out the withdrawal. No SR-17018 involved. People who choose this often describe it as the most direct, but the most physically painful, and with the highest reported relapse rate.
Substitution + taper
Substitute SR-17018 for the original opioid, hold steady for a few days to stabilize, then taper SR-17018 itself in steps. The dominant pattern in community reports. Resembles, in spirit, how methadone or buprenorphine are used clinically — but without medical supervision, validated dosing, or clinical-grade material.
Cold turkey, in detail
What people typically experience (clinical, well-established)
These are not SR-17018-specific — they are general opioid withdrawal symptoms. Most are uncomfortable but not life-threatening in healthy adults; complications can occur with severe dehydration, uncontrolled vomiting, or pre-existing cardiac/psychiatric conditions.
- Hours 8–24 (early): anxiety, restlessness, sweating, runny nose, watery eyes, yawning, gooseflesh, muscle aches
- Hours 24–72 (peak): nausea, vomiting, diarrhea, abdominal cramping, dilated pupils, elevated heart rate and blood pressure, severe insomnia, intense cravings
- Days 4–10 (resolving acute): physical symptoms taper, but exhaustion, low mood, and cravings persist
- Weeks–months (post-acute, "PAWS"): insomnia, anhedonia, mood lability, intermittent cravings
Why community members say they choose it
- No additional substance to source, dose, or trust
- No additional dependence liability layered on existing dependence
- Simplicity — single decision, no ongoing taper to follow
Why community members say they avoid it
- Severity of acute symptoms
- Reported high relapse rate compared to substitution approaches
- Inability to function (work, parent) during the peak window
Substitution + taper, in detail
The dominant pattern in public self-reports[1]. People typically describe three phases. Phase durations are reports, not requirements — actual reports cluster around the ranges shown but vary widely.
Phase 1 — Calibration
≈ 2–3 daysFind a dose that suppresses withdrawal symptoms without producing significant sedation. Reported as low frequent dosing (every 4–8 hours) starting from the low end of community ranges. Adjust upward only if withdrawal symptoms break through. The compound's slow, non-competitive binding kinetics mean the effective dose accumulates over hours, so people who escalate too fast in this phase report over-sedation.
Phase 2 — Maintenance
≈ 4–7 daysHold the calibrated dose and frequency steady. Reports describe this as the period where post-acute withdrawal smooths out and people begin sleeping and eating again. Cravings for the original opioid are reported to decrease through this phase. People who shorten or skip this phase report rougher tapers in the next phase.
Phase 3 — Taper
≈ 7–14 daysReduce dose progressively in steps every 1–3 days. Reports describe small reductions (10–25% per step) as more tolerable than large jumps. The final 25% of the taper is consistently reported as the hardest. Some people describe taking a small final 'bridge' dose every 2–3 days rather than a clean stop.
Reported dose ranges
These numbers are present in public self-reports. They are not recommendations. They are not safe doses. They are not validated. They have not been confirmed to refer to verified-identity material — vendor product is frequently mislabeled or adulterated, which is precisely why we are launching third-party testing.
Scientific deep diveShow the community-reported dose ranges (click to expand)
Reports group roughly by the user's pre-substitution opioid tolerance. Doses are cited as oral, taken with the suspension formulation described in Chemistry.
| Tolerance level | Reported maintenance dose | Reported frequency |
|---|---|---|
| Lower (kratom, prescription opioids, low buprenorphine) | ≈ 25 mg per dose | every 6–8 hours |
| Moderate (oxycodone-equivalent daily use, methadone) | ≈ 50–100 mg per dose | every 6–8 hours |
| High (heavy fentanyl, nitazenes, ODSMT) | ≈ 100–250 mg per dose | multiple times daily |
A consistent thread across reports: smaller, more frequent doses are described as more effective for symptom control than larger, less-frequent doses. This is mechanistically consistent with SR-17018's pharmacokinetics in mice — half-life ~6–8 hours, brain-to-plasma ratio ~3:1[4].
The pattern of low intrinsic efficacy at MOR — and the dependence syndrome demonstrated in mice [2] — should temper any assumption that "more is fine." Doses well above the upper community range produce respiratory depression in animals at oral doses[3].
What people report going wrong
These are recurring patterns from community self-reports. They are also the easiest-to-prevent failure modes:
- Stacking doses too quickly during calibration. Because SR-17018 accumulates over hours rather than peaking quickly, people who re-dose after 1–2 hours when they don't feel an effect report waking up severely over-sedated.
- Skipping or shortening the maintenance phase. Tapering before stabilizing reportedly produces rougher tapers, more cravings, and higher relapse rates.
- Final-step cliff. Going from a low maintenance dose directly to zero is the most-cited cause of post-taper PAWS-like symptoms. People who taper more gradually at the end report better outcomes.
- Returning to the original opioid mid-taper. SR-17018 reduces tolerance to other opioids in animal models. People who relapse to their previous opioid dose mid- or post-taper risk overdose at a previously-tolerated amount. This is the central fatal-overdose pattern with any opioid substitution approach, including buprenorphine and methadone after taper.
- Combining with other CNS depressants. See the next section.
- Material that isn't what the label says. Adulteration with nitazenes or fentanyl analogs has been documented in the broader unregulated opioid supply. Visual inspection cannot rule this out.
Critical interactions
- Benzodiazepines (alprazolam, diazepam, clonazepam, etizolam, designer benzos)
- Alcohol
- Gabapentinoids (gabapentin, pregabalin)
- GHB / GBL / 1,4-BDO
- Other opioids — including the original opioid being tapered from
- Sedating antihistamines in high doses (diphenhydramine, doxylamine)
- Z-drugs (zolpidem, zopiclone)
Long-term toxicity, drug-drug interactions with prescription medications (including QT-prolonging drugs, CYP450 substrates, MAOIs), and safety in patients with hepatic, renal, cardiac, or pulmonary disease are all unknown for SR-17018. See Safety for the full risk framing.
Get medical help
- SAMHSA National Helpline (US): 1-800-662-HELP (4357) · 24/7, free, confidential. Treatment referrals.[5]
- SAMHSA Treatment Locator: findtreatment.gov
- Outside the US: Search for your country's national alcohol and other drug helpline. If immediate medical risk is present, call your local emergency number rather than a helpline.
- If overdose is suspected: Administer naloxone (Narcan) and call emergency services. Repeat doses of naloxone may be needed because SR-17018's duration may exceed naloxone's. See Overdose response.
Legal disclaimer
No medical advice. Nothing on this page, or anywhere on SR17.org, is medical, clinical, pharmaceutical, legal, or psychological advice. Reading this page does not create a clinician–patient relationship of any kind. The content is published for informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any condition.
No endorsement. SR17.org does not recommend, endorse, or encourage the use of SR-17018, any other compound, or any particular self-administration approach. The presence of community-reported numbers, durations, or sequences on this page is descriptive of public self-reports and is not a recommendation that any individual replicate them. There is no clinically validated dosing regimen for SR-17018 in humans.
No warranty. Community-reported information is anecdotal, unverified, subject to selection and survivorship bias, and may reference misidentified or adulterated material. SR17.org makes no representation or warranty, express or implied, regarding the accuracy, completeness, or fitness for any particular purpose of any information on this page. SR17.org disclaims all warranties to the maximum extent permitted by law.
Assumption of risk and release. Any action you take based on the information on this page is at your sole risk. To the maximum extent permitted by applicable law, SR17.org, its operators, contributors, and affiliates are not liable for any direct, indirect, incidental, consequential, or punitive damages arising out of your access to, use of, or reliance on this content.
Legality. Possession, distribution, and use of SR-17018 are governed by national and sub-national law that varies by jurisdiction and changes over time. In the United States, SR-17018 is not specifically scheduled but may be treated as a Schedule I substance under the Federal Analogue Act when intended for human consumption. In Germany, it is controlled under the NpSG. In the United Kingdom, the Psychoactive Substances Act 2016 likely applies. See Legal status for current information and verify with qualified counsel in your jurisdiction. SR17.org does not encourage activity that is unlawful where the reader resides.
Governing law and venue. Your access to this page is conditioned on your acceptance of these terms. To the extent permitted by law, any dispute arising out of your use of this page shall be governed by the laws applicable in the operator's jurisdiction, without regard to conflict-of-laws principles, and resolved exclusively in the courts of that jurisdiction. If any provision of these terms is held unenforceable, the remaining provisions remain in full effect.
Seek professional care. If you are managing opioid dependence, withdrawal, or overdose risk, you should consult a licensed medical professional. Evidence-based medications for opioid use disorder — methadone, buprenorphine, and extended-release naltrexone — are available through licensed clinicians in most countries and are supported by decades of clinical evidence that this compound is not.
Last reviewed: 2026-05-05. Material changes to this page will be reflected in the changelog.
Related reading
Sources cited on this page
- [1]r/Opioid_RCs and r/researchchemicals — community self-reports · Reddit — Anecdotal only; subject to severe selection and survivorship bias
- [2]Kudla L, Bugno R, Podlewska S, et al.. Comparison of an addictive potential of μ-opioid receptor agonists with G protein bias: behavioral and molecular modeling studies · Pharmaceutics, 14(1):55 (2022) pmc.ncbi.nlm.nih.gov/articles/PMC8779292/
- [3]Grim TW, Schmid CL, Stahl EL, et al.. A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal · Neuropsychopharmacology, 45:416–425 (2020) pmc.ncbi.nlm.nih.gov/articles/PMC6901606/
- [4]Pantouli F, Grim TW, Schmid CL, et al.. Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain · Neuropharmacology, 185:108439 (2021) pmc.ncbi.nlm.nih.gov/articles/PMC7887086/
- [5]Opioid Overdose Reversal Medications · SAMHSA www.samhsa.gov/substance-use/treatment/overdose-prevention/opioid-overdose-reversal